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Abstract. the Erm family is composed of the proteins 
ezrin, moesin and radixin, which are cell structure-related 
proteins. despite the detection of viable roles of Erm 
family proteins, the impact of these molecules in cancer 
pathogenesis has yet to be investigated. Evidence emerging 
from clinical and translational studies showed that the Erm 
family is linked to disease progression in clinical cancers. 
We aimed to establish the pattern of expression of the 
Erm proteins and deduce a possible relationship between 
these molecules and clinical outcome in a cohort of human 
breast cancers. the expression of the three Erm molecules 
at the mrna and protein levels in a cohort of 122 human 
breast cancers and 32 normal breast tissues were analysed 
and correlated with pathological and clinical informa-
tion as well as patient outcome. the three molecules were 
positively stained in mammary tissues while the staining 
pattern was lost in the malignant cells. low levels of moesin 
and radixin transcripts were seen in tumours from patients 
with metastasis, local recurrence and in patients who 
succumbed to the disease (moesin: p=0.039, p=0.037 and 
p=0.066, respectively, and radixin: p=0.039, p=0.039 and 
p=0.04, respectively). Ezrin levels were significantly lower 
in tumour recurrence and in patients who succumbed to 
the disease (p=0.0001 and p=0.59, respectively). using the 
Kaplan-meier survival analysis, a general trend of higher 
levels of Erm was observed, with marginal long overall and 
disease-free survival. in conclusion, an inverse relationship 
between Erm expression and tumour behaviour of breast 
cancer patients was noted. however, further work needs to 
be conducted in other types of cancer in clinical situations 
to obtain consistent results.
Introduction
the Erm family is composed of the proteins ezrin, moesin 
and radixin, which are cell structure-related proteins (1). their 
sequence of the amino-terminal halves (300 amino acids) is 
highly conserved and is found in band 4.1, an erythrocyte 
membrane protein. together the proteins are called the band 
4.1 superfamily and their common domain is referred to as 
the FErm domain, in combination with merlin/schwannomin, 
the nF2 tumour suppressor protein and talin. these highly 
homologous proteins constitute a family with structural and 
viable relationships. moreover, the proteins are localized to 
the submembranous cytoskeleton and are traditionally known 
as molecules responsible for maintaining cell integrity and 
morphology. Erm proteins are also involved in the binding 
process between the plasma membrane and the actin 
cytoskeleton, and are involved in a variety of cellular functions, 
such as cell adhesion, migration and the organization of cell 
surface structures.
it has been suggested that radixin is involved in anchoring 
the ‘pointed’ ends of actin filaments to the membrane in 
stereocilia (2). using antigen-activated t cells, Erm proteins 
regulate cytoskeleton relaxation and promote t cell-apc 
(antigen-presenting cell) conjugation. Ezrin-radixin-moesin 
(Erm) proteins are rapidly inactivated through a VaV1-rac1 
pathway (3). the resulting disanchoring of the cortical actin 
cytoskeleton from the plasma membrane decreased cellular 
rigidity, resulting in a more efficient T cell-APC conjugate 
formation. thus, this pathway favours immunological synapse 
formation and the development of an effective immune 
response.
Ezrin was shown to act as an anchorage protein for cd44, 
a cell adhesion molecule that is widely involved in metastatic 
cells, as well as icam2 (4). We reported that ezrin interacts 
with the cadherin complex and co-ordinates the cell-cell 
adhesion mechanisms in epithelial cells (5). thus, the above 
studies showed that the disruption or deletion of ezrin and its 
family members disrupted homotypic and heterotypic cell-cell 
adhesion. Erm protein functions, and their link to cd44 and 
icam2, suggest a potential role of the Erm family in cancer 
invasion and metastasis.
despite the detection of the viable roles of Erm family 
proteins, the impact of these molecules in cancer pathogenesis 
has yet to be investigated. Evidence emerging from clinical 
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and translational studies showed that the Erm family is 
linked to disease progression in clinical cancers. For example, 
in patients with head and neck squamous cell carcinoma, 
high levels of ezrin protein staining were associated with a 
shorter survival (6). in prostate tissues, ezrin immunoreac-
tivity is associated with the gleason score and seminal vesicle 
invasion of the patients (7). in paediatric soft tissue sarcoma 
(sts), high levels of ezrin immunoreactivity are associated 
with disease-free and overall survival of the patients (8). using 
a tissue microarray of >5000 tumours, bruce et al (9) have 
shown that a link exists between ezrin and clinical outcome in 
patients with a variety of tumour types. 
in the present study, we aimed to establish the pattern of 
expression of the Erm proteins and deduce a possible rela-
tionship between these molecules and clinical outcome in a 
cohort of human breast cancers.
Materials and methods
Materials. rna extraction and rt kits were obtained from 
abgene ltd., surrey, England, uK. pcr primers were 
designed using beacon designer (ca, usa) and synthesised 
by invitrogen ltd. (pasley, scotland, uK). molecular biology 
grade agarose and dna ladder were purchased from invitrogen 
(pasley). master mix for routine pcr and customised master 
mix for quantitative pcr were from abgene. polyclonal anti-
body to human moesin and radixin, and mouse monoclonal 
antibody to human ezrin were purchased from santa cruz 
Biotechnology Ltd. (Santa Cruz, CA, USA) and Affinity 
antibodies, inc. (Exeter, England, uK), respectively. anti-Er 
(543) and anti-Er-β (8974) antibodies were purchased from 
santa cruz biotechnology, inc. peroxidase conjugated 
anti-rabbit and anti-goat antibodies were from sigma and a 
biotin universal staining kit was from Vector laboratories 
(nottingham, England, uK).
Cells and tissue samples. breast cancer tissues (n=120) and 
normal background tissues (n=32) were collected immediately 
after surgery and stored in the deep freezer until use. details of 
histology and clinical outcome were obtained from pathology 
reports as was previously reported (table i). patients were 
routinely followed after surgery. the median follow-up period 
was 120 months. the presence of tumour cells in the collected 
tissues was verified by a consultant pathologist who examined 
h&E-stained frozen sections (10,11).
Tissue processing, RNA extraction, cDNA synthesis and 
RT-PCR. Frozen sections of tissues were cut at 5-10 µm and 
were kept for immunohistochemistry and routine histology 
(12). a further 15-20 sections were mixed and homogenised 
using a hand-held homogeniser, in ice-cold rna extraction 
solution. rna concentration was determined using a uV 
spectrophotometer. reverse transcription was carried out 
using a rt kit with an anchored oligo(dt) primer supplied by 
abgene, and 1 pg total rna in a 96-well plate. the quality of 
cDNA was verified using β-actin primers.
Quantitative analysis of ezrin, radixin and moesin transcripts. 
the level of Erm transcripts from the cdna prepared as 
above was determined using a real-time quantitative pcr, 
based on the Amplifluor™ technology as previously reported 
(13,14), which has been modified from a method previously 
described (13). Briefly, PCR primer pairs were designed 
using the beacon designer software (version 2, ca, usa) 
(sequence given in table ii). an additional sequence, known 
as the Z sequence (5'actgaacctgaccgtaca'3), which is comple-
mentary to the universal Z probe (13) (intergen inc., England, 
uK), was added to one of the primers. a taqman detection kit 
for β-actin was purchased from perkin-Elmer. the reaction was 
carried out using hot-start Q-master mix (abgene), 10 pmol of 
specific forward primer, 10 pmol reverse primer which has the 
Z sequence, 100 pmol of 6-carboxyfluorescein FAM-tagged 
probe (intergen inc.) and cdna from ~50 ng rna. the reac-
tion was carried out using Icycler IQ™ (Bio-Rad) which is 
equipped with an optic unit that allows real-time detection of 
96 reactions, using the conditions: 94˚C for 12 min, 50 cycles 
of 94˚C for 15 sec, 55˚C for 40 sec and 72˚C for 20 sec 
(13,15,16). Primers used for quantification of the oestrogen 
receptor (Er) and Er-β were as previously reported (17). 
cytokeratin-19 (cK19) was used to compare cellularity 
during the analysis (18). transcript levels were generated from 
an internal standard (12) that was simultaneously amplified 
with the samples. the transcript levels were based on equal 
amounts of rna and as a target/cK19 ratio.
table i. clinicopathological details of the study cohort.
clinical information no.
nodal status
   negative 65
   positive 55
grade
   1 23
   2 41
   3 56
histology
   ductal 94
   lobular 14
   medullary 2
   tubular 2
   mucinous 4
   other 4
tnm staging
   tnm 1 69
   tnm 2 40
   tnm 3 7
   tnm 4 4
clinical outcome
   disease-free 81
   metastasis 7
   local recurrence 5
   succumbed to breast cancer 20
   succumbed to unrelated disease 7
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Immunohistochemical staining of ezrin, radixin and moesin. 
immunohistochemical staining was based on a method 
described earlier (16). Frozen sections of breast tumours 
and background tissues were cut at 6 µm using a cryostat. 
the sections were mounted on superfrost plus microscope 
slides, air dried and fixed in a mixture of 50% acetone and 
50% methanol. The staining procedure was completed simul-
taneously for the section, to ensure comparison. the sections 
were then placed in optimax wash buffer for 5-10 min to 
rehydrate. Sections were incubated for 20 min in a 0.6% 
bsa blocking solution and probed with the primary antibody 
(diluted at 1:100 for anti-moesin and anti-radixin and 1:50 
for anti-ezrin). Following extensive washings, sections were 
incubated for 30 min in the secondary biotinylated antibody 
(multilink swine anti-goat/mouse/rabbit immunoglobulin, 
dako inc.). Following washings, the avidin-biotin complex 
(Vector laboratories) was applied to the sections followed by 
extensive washings. diaminobenzidine chromogen (Vector 
laboratories) was added to the sections which were incubated 
in the dark for 5 min. sections were counterstained in gill's 
haematoxylin and dehydrated in ascending grades of meth-
anol before they were cleared in xylene and mounted under 
a cover slip. the staining intensity of the respective proteins 
in the cytoplasmic area and nucleus was semi-quantified 
from non-counterstained images, using a method established 
in our laboratory (18,19). Briefly, grayscale digitized images 
were imported into the optimas software (optimas 6.0). the 
staining intensity was analysed in the nucleus and cytoplasmic 
compartments. control staining (without primary antibody) 
was used for extraction of the background staining. intensity 
data were exported to Excel for statistical analysis and are 
shown here as the mean intensity of either the cytoplasmic 
region or nucleus staining.
statistical analysis was carried out using the mann-
Whitney u and Kruskal-Wallis tests, and the Kaplan-meier 
survival and cox proportional analysis where appropriate, 
using an spss (version 12) package.
Results
Distribution of ezrin, radixin and moesin family in mammary 
tissues. the three molecules were positively stained in 
Figure 1. immunohistochemical staining of ezrin (left panel), moesin (middle panel) and radixin (right panel) in normal mammary tissue (left column in the 
respective panel) and breast tumour tissue (right in the respective panel). Staining is shown at varying magnifications.
table ii. primer sequences (underlined sections are the Z-sequence for quantification).
 sense (5'-'3) antisense (5'-'3)
Ezrin agatgagcagtctgccttt actgaacctgaccgtacacaacatgagagattgggaaaga
moesin cgacagaagaaggagagtga actgaacctgaccgtacaggtgtactcatggcagtctt
radixin gaccagatgaagaatcagga actgaacctgaccgtacaagttgcttccctcttcctttt
cK19 quantification caggtccgaggttactgac actgaacctgaccgtacacactttctgccagtgtgtcttc
Er cctactacctggagaacgag ctcttcggtcttttcgtatg
Er-β aaaagaatcattcaatgaca attaacacctccatccaaca
β-actin atgatatcgccgcgctcg cgctcgtgtaggatcttca
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mammary tissues (Fig. 1). in normal tissues, ezrin promi-
nently stained in epithelial cells. its location is primarily on 
the luminal side and intercellular region of the epithelial cells. 
the luminal side of distribution is of particular interest, as 
ezrin is known to be rich in the microvilli area of the cells. 
the same distribution pattern was seen with radixin in normal 
mammary epithelial cells (Fig. 1, right panel), while that of 
moesin is less distinct.
of note is that breast cancer cells have lost the staining 
pattern for the three molecules as was observed in normal 
epithelium.
Differential pattern of expression of the ezrin, radixin and 
moesin family in non-neoplastic and tumour tissues. transcript 
levels of the three members were quantified using real-time 
quantitative pcr. as shown in Fig. 2, there were margin-
ally low levels of ezrin (p=0.54) and high levels of moesin 
(p=0.12) in tumour tissues compared with normal tissues. a 
similar trend was observed after normalisation with cK19 
(Fig. 2, right panel). however, radixin transcript levels were 
significantly higher in tumour tissues (p=0.028), as was the 
radixin cK19 ratio (Fig. 2, right panel).
Correlation between ezrin, radixin and moesin proteins, 
nodal status and tumour grade. transcript levels were 
analysed against tumour grade (Fig. 3), nodal status (Fig. 4) 
and predicted clinical prognosis, based on the nottingham 
Prognostic Index (Fig. 5), but no significant difference was 
noted. However, there appear to be significant low levels of 
ezrin transcripts in tnm3 and tnm4 tumours (p=0.0017 and 
p=0.006, respectively) (Fig. 6). No significant difference was 
noted for moesin and radixin.
Relationship between transcript levels of ezrin, radixin and 
moesin family members with clinical outcomes. as shown in 
Fig. 7, moesin and radixin levels together with their respec-
Figure 2. levels of expression are shown in the left panel for (a) ezrin, (b) 
moesin and (c) radixin in normal and tumour tissues. *p<0.05 compared 
with normal tissues. right panel: ezrin, moesin and radixin cK19 ratios, 
respectively.
Figure 3. levels of expression are shown in the left panel for (a) ezrin, (b) 
moesin and (c) radixin in relation to the tumour grade. right panel: respective 
Erm cK19 ratios.
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tive ratios to cK19 were inversely correlated with the patient 
outcome. low levels of moesin and radixin transcripts and 
lower ratios to cK19 were noted in tumours obtained from 
patients with metastasis, local recurrence and in patients 
who succumbed to the disease (moesin: p=0.039, p=0.037 
and p=0.066, respectively, and radixin: p=0.039, p=0.039 
and p=0.04, respectively) (Fig. 7b and c). although the 
levels of ezrin transcripts appear to be marginally higher in 
tumours associated with metastasis (p=0.53), the levels were 
significantly lower in tumour recurrence and in patients who 
succumbed to the disease (p=0.0001 and p=0.59) (Fig. 7). 
interestingly, the ezrin:cK19 ratio has shown a low level of 
survival in patients with metastasis, recurrence or mortality, 
compared with those who remained disease-free.
using the Kaplan-meier survival analysis, a general trend 
of higher levels of Erm was observed with marginal long 
overall (Fig. 8, left panel) and disease-free survival (Fig. 8, 
right panel). However, no statistical significance was noted.
Discussion
The present study is the first to report the association between 
the proteins belonging to the band 4.1 superfamily and breast 
cancer. the Erm subgroup of the superfamily has consistently 
been found to be co-expressed in the majority of cultured cells 
(1). in humans, the proteins have been found to have a tissue-
specific expression pattern (1). High concentrations of ezrin 
are found in the lung, gut and the kidney while high levels of 
radixin occur in the liver and intestine (21). While endothe-
lial cells express moesin, ezrin is expressed in epithelial and 
mesothelial cells (1). Erm molecules are found in high levels 
of actin-rich surface structures such as microvilli, filopodia 
and membrane ruffles (22). These are the vital structures 
required for the microinvasion and metastasis of cancer cells. 
the suppression of Erm expression by anti-sense oligo-
nucleotides results in the destruction of the cell-substrate and 
cell-cell adhesion in colorectal cell lines (5) and thymoma 
Figure 4. levels of expression are shown in the left panel for (a) ezrin, (b) 
moesin and (c) radixin in node-negative and node-positive tumours. right 
panel: respective Erm cK19 ratios.
Figure 5. Expression of (a) ezrin, (b) moesin and (c) radixin in relation to 
the nottingham prognostic index (npi), where npi-1 (<3.4) indicates good 
prognosis, npi-2 (3.4-5.4) moderate and npi-3 (>5.4) poor prognosis. right 
panel: respective Erm cK19 ratios.
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cells. similarly it has been shown that the suppression of Erm 
expression resulted in the disappearance of microvilli from 
the cell surface (23). therefore, if a link is found between the 
expression of these molecules and metastasis of breast cancer 
in patients, appropriate therapy may be employed to arrest the 
metastasis of the disease.
this study has revealed interesting associations between 
the Erm family and the clinical course of breast cancer. 
such associations are observed between a higher incidence 
of recurrence and metastasis to low expression levels of the 
Erm family in the tumour tissues. the Kaplan-meier analysis 
showed that a marginal overall improved survival occured 
in patients who had a higher expression of these proteins in 
their tumour tissue. therefore, these results suggest an inverse 
relationship between ERM expression and survival benefit. 
We previously reported that following the inhibition of 
colorectal cancer cell lines using antisense nucleotides, these 
cells displayed a reduced cell-cell adhesion together with an 
increase in their motile and invasive behaviour. a correlation 
of the two studies shows that this mechanism also extends 
to breast cancer; thus, a higher incidence of recurrence and 
metastasis occurred in those cases with a low expression. 
therefore, these results are important in predicting the tumour 
behaviour of these patients post-surgery.
the present study, together with that of bruce et al (9) 
indicated that ezrin and other members of the Erm family 
are aberrant in their expression in breast cancer. this occurs 
at the protein [the present and bruce et al (9)] and messenger 
level (the present study). a clinical connection exists since 
aberrant levels are associated with disease progression and 
clinical outcome. however, this connection appears to be weak 
in adenocarcinomas when compared to that observed in other 
tumour types, i.e. sarcomas and head and neck squamous cell 
carcinomas. Ezrin was found to be overexpressed in high-
grade prostatic intraepithelial neoplasia (hgpin) and prostate 
cancer compared with the adjacent benign prostatic epithelium. 
Figure 6. levels of expression are shown in the left panel for (a) ezrin, (b) 
moesin and (c) radixin in relation to tnm staging. right panel: respective 
Erm cK19 ratios.
Figure 7. levels of expression are shown in the left panel for (a) ezrin, 
(b) moesin and (c) radixin, as well as the clinical outcome over a 6-year 
follow-up period. the number of patients who remained disease-free, devel-
oped metastasis, had local recurrence and succumbed to the disease is shown. 
right panel: respective Erm cK19 ratios.
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in addition, hgpin has a greater expression level of ezrin 
compared with that of prostate cancer. the above studies also 
indicated that the aberrant expression of ezrin is involved in 
the pathogenesis of prostate cancer; thus, ezrin expression may 
be useful for the diagnosis of hgpin (7). Ezrin represents 
a promising therapeutic target for patients with advanced-
stage rhabdomyosarcoma (24). a high ezrin expression in 
the primary tumour of initially metastasis-free sts patients 
is strongly associated with the development of metastases 
during follow-up, and consequently with poor survival (8). 
a high ezrin expression in dog tumours was associated with 
early development of metastases. consistent with these data, 
a significant association between a high ezrin expression and 
poor outcome was found in paediatric osteosarcoma patients 
(25). the expression pattern of ezrin in particular, and of the 
Erm family members in general, is contrary to the clinical 
pattern of disease progression in adenocarcinomas as compared 
to soft tissue sarcomas and other mesenchymal tumours.
Figure 8. levels of Erm family members and correlation with survival. dark lines indicate low levels and grey lines indicate high levels of the respective 
family member.
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in conclusion, an inverse relationship between Erm 
expression and tumour behaviour of breast cancer patients 
was noted. Further studies, however, need to be conducted in 
other cancer types in clinical situations to obtain consistent 
results.
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